{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:45:02Z","timestamp":1762508702749},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T00:00:00Z","timestamp":1643587200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T00:00:00Z","timestamp":1643587200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Wujin District Project Foundation","award":["WS202011"],"award-info":[{"award-number":["WS202011"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>The objective of this meta-analysis was to compare the efficacy and safety of tacrolimus (TAC) monotherapy versus corticosteroid as initial monotherapy in adult-onset minimal change disease (MCD) patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Databases including PubMed, Embase, the Cochrane Library, China National Knowledge Infrastructure, and Wanfang database were searched from the inception to\u00a0March 20, 2021. Eligible studies comparing TAC monotherapy and corticosteroid as initial monotherapy for adult-onset MCD patients were included. Data were analyzed using Review Manager Version 5.3.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Four randomized controlled trials (RCTs) involving 196 patients were included in the meta-analysis. For initial monotherapy for adult-onset MCD, TAC and corticosteroid had similar complete remission (OR 1.06, 95% CI 0.47\u20132.41, <jats:italic>P<\/jats:italic>\u2009=\u20090.89), total remission (OR 1.30, 95% CI 0.39\u20134.35, <jats:italic>P<\/jats:italic>\u2009=\u20090.67), relapse rate (OR 0.63, 95% CI 0.28\u20131.42, <jats:italic>P<\/jats:italic>\u2009=\u20090.26). Main drug-related adverse effects of two therapeutic regimens had no difference concerning infection (OR 0.54, 95% CI 0.23\u20131.27, <jats:italic>P<\/jats:italic>\u2009=\u20090.15), glucose intolerance (OR 0.55, 95% CI 0.16\u20131.84, <jats:italic>P<\/jats:italic>\u2009=\u20090.33) and acute renal failure (OR 1.37, 95% CI 0.36\u20137.31, <jats:italic>P<\/jats:italic>\u2009=\u20090.71).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>TAC monotherapy is comparable with corticosteroid monotherapy in initial therapy of MCD. To further confirm the conclusion, more large multicenter RCTs are necessary.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11255-022-03122-7","type":"journal-article","created":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T18:02:42Z","timestamp":1643652162000},"page":"2205-2213","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy and safety of tacrolimus versus corticosteroid as initial monotherapy in adult-onset minimal change disease: a meta-analysis"],"prefix":"10.1007","volume":"54","author":[{"given":"Jingkui","family":"Lu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhongxiu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lifeng","family":"Gong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weigang","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fengyan","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liping","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoli","family":"Qian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,1,31]]},"reference":[{"key":"3122_CR1","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1136\/bmj.39576.709711.80","volume":"336","author":"RP Hull","year":"2008","unstructured":"Hull RP, Goldsmith DJ (2008) Nephrotic syndrome in adults. BMJ 336:1185\u20131189","journal-title":"BMJ"},{"key":"3122_CR2","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1159\/000046215","volume":"21","author":"JJ Huang","year":"2001","unstructured":"Huang JJ, Hsu SC, Chen FF (2001) Adult-onset minimal change disease among Taiwanese: clinical features, therapeutic response, and prognosis. Am J Nephrol 21:28\u201334","journal-title":"Am J Nephrol"},{"key":"3122_CR3","doi-asserted-by":"publisher","first-page":"513","DOI":"10.2215\/CJN.10131011","volume":"7","author":"BA Kerlin","year":"2012","unstructured":"Kerlin BA, Ayoob R, Smoyer WE (2012) Epidemiology and pathophysiology of nephrotic syndrome-associated thromboembolic disease. Clin J Am Soc Nephrol 7:513\u2013520","journal-title":"Clin J Am Soc Nephrol"},{"key":"3122_CR4","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/S0272-6386(12)70179-8","volume":"22","author":"J Radhakrishnan","year":"1993","unstructured":"Radhakrishnan J, Appel AS, Valeri A (1993) The nephrotic syndrome, lipids, and risk factors for cardiovascular disease. Am J Kidney Dis 22:135\u2013142","journal-title":"Am J Kidney Dis"},{"key":"3122_CR5","doi-asserted-by":"publisher","first-page":"445","DOI":"10.2215\/CJN.03531006","volume":"2","author":"M Waldman","year":"2007","unstructured":"Waldman M, Crew RJ, Valeri A (2007) Adult minimal-change disease: clinical characteristics, treatment, and outcomes. Clin J Am Soc Nephrol 2:445\u2013453","journal-title":"Clin J Am Soc Nephrol"},{"key":"3122_CR6","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/kisup.2012.19","volume":"2","author":"KDIGO","year":"2012","unstructured":"KDIGO (2012) Clinical practice guidelines for glomerulonephritis. kidney disease: improving global outcomes. Kidney Int Suppl 2:181\u2013185","journal-title":"Kidney Int Suppl"},{"issue":"7","key":"3122_CR7","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1093\/ndt\/gfg134","volume":"18","author":"KC Tse","year":"2003","unstructured":"Tse KC, Lam MF, Yip PS (2003) Idiopathic minimal change nephrotic syndrome in older adults: steroid responsiveness and pattern of relapses. Nephrol Dial Transplant 18(7):1316\u20131320","journal-title":"Nephrol Dial Transplant"},{"key":"3122_CR8","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.2215\/CJN.12331213","volume":"9","author":"M Shinzawa","year":"2014","unstructured":"Shinzawa M, Yamamoto R, Nagasawa Y (2014) Comparison of methylprednisolone plus prednisolone with prednisolone alone as initial treatment in adult-onset minimal change disease: a retrospective cohort study. Clin J Am Soc Nephrol 9:1040\u20131048","journal-title":"Clin J Am Soc Nephrol"},{"key":"3122_CR9","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1093\/ndt\/gfp422","volume":"25","author":"A Eguchi","year":"2010","unstructured":"Eguchi A, Takei T, Yoshida T (2010) Combined cyclosporine and prednisolone therapy in adult patients with the first relapse of minimal-change nephrotic syndrome. Nephrol Dial Transplant 25:124\u2013129","journal-title":"Nephrol Dial Transplant"},{"key":"3122_CR10","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.trim.2009.07.001","volume":"22","author":"MC Rauch","year":"2009","unstructured":"Rauch MC, San Mart\u00edn A (2009) Tacrolimus causes a blockage of protein secretion which reinforces its immunosuppressive activity and also explains some of its toxic side-effects. Transpl Immunol 22:72\u201381","journal-title":"Transpl Immunol"},{"key":"3122_CR11","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1111\/j.1432-2277.2005.00080.x","volume":"18","author":"AG Jardine","year":"2005","unstructured":"Jardine AG (2005) Assessing the relative risk of cardiovascu lar disease among renal transplant patients receiving tacrolimus or cyclosporine. Transpl Int 18:379\u2013384","journal-title":"Transpl Int"},{"key":"3122_CR12","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1111\/j.1600-6143.2006.01300.x","volume":"6","author":"M Grimm","year":"2006","unstructured":"Grimm M, Rinaldi M, Yonan NA (2006) Superior prevention of acute rejection by tacrolimus vs. cyclosporine in heart transplant recipients-a large European trial. Am J Transplant 6:1387\u20131397","journal-title":"Am J Transplant"},{"key":"3122_CR13","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1053\/j.ajkd.2008.11.033","volume":"53","author":"S Choudhry","year":"2009","unstructured":"Choudhry S, Bagga A, Hari P (2009) Effificacy and safety of tacrolimus versus cyclosporine in children with steroid-resistant nephrotic syndrome: a randomized controlled trial. Am J Kidney Dis 53:760\u2013769","journal-title":"Am J Kidney Dis"},{"key":"3122_CR14","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1016\/j.clinthera.2012.03.008","volume":"34","author":"H Li","year":"2012","unstructured":"Li H, Shi X, Shen H (2012) Tacrolimus versus intravenous pulse cyclophosphamide therapy in Chinese adults with steroid-resistant idiopathic minimal change nephropathy: a multicenter, open-label, nonrandomized cohort trial. Clin Ther 34:1112\u20131120","journal-title":"Clin Ther"},{"key":"3122_CR15","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1093\/ndt\/gfm637","volume":"23","author":"X Li","year":"2008","unstructured":"Li X, Li H, Chen J (2008) Tacrolimus as a steroid-sparing agent for adults with steroid dependent minimal change nephrotic syndrome. Nephrol Dial Transplant 23:1919\u20131925","journal-title":"Nephrol Dial Transplant"},{"key":"3122_CR16","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1097\/BRS.0000000000001061","volume":"40","author":"AD Furlan","year":"2015","unstructured":"Furlan AD, Malmivaara A, Chou R (2015) 2015 Updated method guideline for systematic reviews in the Cochrane back and neck group. Spine 40:1660\u20131673","journal-title":"Spine"},{"issue":"9","key":"3122_CR17","first-page":"153","volume":"24","author":"J Li","year":"2012","unstructured":"Li J, Yao LL, Jin L (2012) Clinical study of tacrolimus monotherapy in the treatment of minimal change nephrotic syndrome. Strait Pharm J 24(9):153\u2013156","journal-title":"Strait Pharm J"},{"key":"3122_CR18","unstructured":"Li XY, Xu N, Chen JH (2012) Comparison of short-term intravenous methylprednisolone after tacrolimus monotherapy and standard steroid regimen in the treatment of adult-onset minimal change disease: a prospective, open, randomized, controlled, multi-center clinical study. Zhejiang nephrology academic annual conference proceedings. pp 161\u2013162"},{"issue":"1","key":"3122_CR19","doi-asserted-by":"publisher","first-page":"129","DOI":"10.4103\/1319-2442.252902","volume":"30","author":"MR Patil","year":"2019","unstructured":"Patil MR, Divyaveer SS, Raychaudhary A (2019) Tacrolimus as the first-line agent in adult-onset minimal change disease: a randomized controlled study. Saudi J Kidney Dis Transpl 30(1):129\u2013137","journal-title":"Saudi J Kidney Dis Transpl"},{"issue":"2","key":"3122_CR20","doi-asserted-by":"publisher","first-page":"209","DOI":"10.2215\/CJN.06180519","volume":"15","author":"NR Medjeral-Thomas","year":"2020","unstructured":"Medjeral-Thomas NR, Lawrence C, Condon M (2020) Randomized, controlled trial of tacrolimus and prednisolone monotherapy for adults with de novo minimal change disease: a multicenter, randomized, controlled trial. Clin J Am Soc Nephrol 15(2):209\u2013218","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"3122_CR21","doi-asserted-by":"publisher","first-page":"393","DOI":"10.5414\/CNP65393","volume":"65","author":"TH Westhoff","year":"2006","unstructured":"Westhoff TH, Schmidt S, Zidek W (2006) Tacrolimus in steroid-resis- t ant and st eroid-dependent nephrotic syndrome. Clin Neph rol 65(6):393\u2013400","journal-title":"Clin Neph rol"},{"issue":"3","key":"3122_CR22","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s00467-003-1370-3","volume":"19","author":"K Loeffler","year":"2004","unstructured":"Loeffler K, Gowrishankar M, Yiu V (2004) Tacrolimus therapy in pediatric patients with treatment-resist ant nephrotic syndrome. Pediatr Nephrol 19(3):281\u2013287","journal-title":"Pediatr Nephrol"},{"issue":"7","key":"3122_CR23","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1093\/ndt\/gfi274","volume":"21","author":"MD Sinha","year":"2006","unstructured":"Sinha MD, Macleod R, Rigby E (2006) Treatment of severe st eroid-de-pendent nephrotic syndrome (SDNS)in children with tacrolimus. Nephrol Dial T ransplant 21(7):1848\u20131854","journal-title":"Nephrol Dial T ransplant"},{"key":"3122_CR24","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1053\/j.ajkd.2014.09.022","volume":"65","author":"CC Szeto","year":"2015","unstructured":"Szeto CC, Lai FM, Chow KM (2015) Long-term outcome of biopsy-proven minimal change nephropathy in Chinese adults. Am J Kidney Dis 65:710\u2013718","journal-title":"Am J Kidney Dis"},{"key":"3122_CR25","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/S0002-9343(01)00659-3","volume":"110","author":"CC Szeto","year":"2001","unstructured":"Szeto CC, Lai FM, To KF (2001) The natural history of immunoglobulin a nephropathy among patients with hematuria and minimal proteinuria. Am J Med 110:434\u2013437","journal-title":"Am J Med"},{"issue":"4","key":"3122_CR26","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1093\/ndt\/17.4.655","volume":"17","author":"A Segarra","year":"2002","unstructured":"Segarra A, Vila J, Pou L (2002) Combined therapy of tacrolimus and corticosteroids in cyclosporin-resistant or -dependent idiopathic focal glomerulosclerosis: a preliminary uncontrolled study with prospective follow-up. Nephrol Dial Transplant 17(4):655\u2013662","journal-title":"Nephrol Dial Transplant"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-022-03122-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-022-03122-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-022-03122-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T10:35:47Z","timestamp":1660214147000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-022-03122-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,31]]},"references-count":26,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,9]]}},"alternative-id":["3122"],"URL":"https:\/\/doi.org\/10.1007\/s11255-022-03122-7","relation":{},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,31]]},"assertion":[{"value":"7 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}